
Fleroxacin
CAS No. 79660-72-3
Fleroxacin( Fleroxacin, Quinodis, Megalocin, AM-833, Ro 236240 )
Catalog No. M19364 CAS No. 79660-72-3
Fleroxacin is a broad-spectrum antimicrobial fluoroquinolone. It strongly inhibits the DNA-supercoiling activity of DNA gyrase.
Purity : >98% (HPLC)






Size | Price / USD | Stock | Quantity |
500MG | 37 | In Stock |
![]() ![]() |
1G | 59 | In Stock |
![]() ![]() |
Biological Information
-
Product NameFleroxacin
-
NoteResearch use only, not for human use.
-
Brief DescriptionFleroxacin is a broad-spectrum antimicrobial fluoroquinolone. It strongly inhibits the DNA-supercoiling activity of DNA gyrase.
-
DescriptionFleroxacin, a quinolone, is a bactericidal drug that inhibits bacterial DNA gyrase and topoisomerase IV. Like other quinolones and fluoroquinolones the compound eradicates bacteria by interfering with DNA replication (bacterial DNA replication, transcription, repair and recombination). Fleroxacin is active against many Gram-positive and Gram-negative bacteria.(In Vivo):Fleroxacin (Ro 23-6240) is a new trifluorinated quinolone exhibiting high activity against a broad spectrum of gram-negative and gram-positive bacteria. Fleroxacin is characterized pharmacokinetically by a long elimination half-life (9 to 10 h) and high concentrations in plasma (e.g., maximum concentration of 2.3 micrograms/ml after an oral dose of 200 mg). Fleroxacin (Ro 23-6240) is effective against Haemophilus ducreyi in vitro. Fleroxacin (Ro 23-6240), 200 or 400 mg as a single oral dose, is efficacious therapy for microbiologically proven chancroid in patients who do not have concurrent HIV-1 infection. Among HIV-1-infected men, a single dose of 200 or 400 mg of fleroxacin is inadequate therapy for chancroid.
-
In Vitro——
-
In VivoFleroxacin (Ro 23-6240) is a new trifluorinated quinolone exhibiting high activity against a broad spectrum of gram-negative and gram-positive bacteria. Fleroxacin is characterized pharmacokinetically by a long elimination half-life (9 to 10 h) and high concentrations in plasma (e.g., maximum concentration of 2.3 micrograms/ml after an oral dose of 200 mg). Fleroxacin (Ro 23-6240) is effective against Haemophilus ducreyi in vitro. Fleroxacin (Ro 23-6240), 200 or 400 mg as a single oral dose, is efficacious therapy for microbiologically proven chancroid in patients who do not have concurrent HIV-1 infection. Among HIV-1-infected men, a single dose of 200 or 400 mg of fleroxacin is inadequate therapy for chancroid.
-
SynonymsFleroxacin, Quinodis, Megalocin, AM-833, Ro 236240
-
PathwayOthers
-
TargetOther Targets
-
RecptorDNA gyrase| Topo II| Topo IV
-
Research AreaInfection
-
Indication——
Chemical Information
-
CAS Number79660-72-3
-
Formula Weight369.34
-
Molecular FormulaC17H18F3N3O3
-
Purity>98% (HPLC)
-
SolubilityDMSO : < 1 mg/mL
-
SMILESCN1CCN(CC1)C2=C(C=C3C(=C2F)N(C=C(C3=O)C(=O)O)CCF)F
-
Chemical Name6,8-difluoro-1-(2-fluoroethyl)-7-(4-methylpiperazin-1-yl)-4-oxoquinoline-3-carboxylic acid
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Hussy P, et al. Antimicrob Agents ChemOthers. 1986 Jun;29(6):1073-8.
molnova catalog



related products
-
12beta-Acetoxy-3,7,1...
The fruit body of Ganoderma lucidum.
-
5-HT2B antagonist-1
5-HT2B antagonist-1 is an orally active 5-HT2B receptor antagonist with an IC50 of 33.4 nM, suitable for studies of diseases characterized by 5-HT2B receptor signaling, such as hepatocellular carcinoma, cardiovascular disease, or gastrointestinal disease .
-
MI-3454
MI-3454 is an orally active, selective and potent inhibitor of Menin-MLL1 interaction that inhibits the proliferation and induces differentiation of acute leukemia cells with MLL1 translocation or NPM1 mutation.